In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market size was over USD 1.83 billion in 2023 and is projected to reach USD 3.58 billion by 2036, growing at around 5.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of in-vitro IBD diagnostic is assessed at USD 1.91 billion.
The growth of the market can be primarily attributed to the growing prevalence of inflammatory bowel disease worldwide, and therefore the need amongst individuals to diagnose the disease. Moreover, the market is also anticipated to grow on account of the growing healthcare expenditure and the rising research activities in the field of gastro sciences.
The in-vitro inflammatory bowel disease (IBD) diagnostic market is also expected to grow on account of the growing concern for the increasing incidences of digestive diseases worldwide and the increasing awareness amongst individuals to treat such diseases. According to the statistics by the Institute for Health Metrics and Evaluation (IHME), deaths caused due to digestive diseases around the globe increased from 726331.36 deaths in the year 2000 to 939281 deaths in the year 2019.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
5.3% |
|
Base Year Market Size (2023) |
USD 1.83 billion |
|
Forecast Year Market Size (2036) |
USD 3.58 billion |
|
Regional Scope |
|
The in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented by product into assays/biomarkers and analyzers. Out of these, the assays/biomarkers segment is anticipated to hold the highest market share throughout the forecast period. The segment is also anticipated to grow with the highest CAGR of 5.6% during the forecast period. Further, on the basis of disease type, the market is segmented into ulcerative colitis and Crohn’s disease, out of which, the ulcerative colitis segment is anticipated to hold the highest market share and also grow with the highest CAGR of 5.7% during the forecast period. Based on disease stage, the market is segmented into mild, moderate, and severe, out of which, the severe segment is anticipated to hold the largest market revenue of USD 1225.89 Million by the end of 2028, up from a revenue of USD 823.27 Million in 2019. Further, on the basis of test type, the in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented into blood tests, stool tests, antibody tests, and biopsy. Out of these segments, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of USD 931.51 Million by the end of 2028. On the basis of patient demography, the market is segmented into pediatric, adults, and geriatric, out of which, the adults segment is anticipated to hold the largest revenue of USD 1592.15 Million by the end of 2028. The market is also segmented on the basis of end-user into hospitals, clinics, diagnostic laboratories, and others. Out of these segments, the hospitals segment is projected to hold the highest market share and also attain a revenue of USD 1297.52 Million by the end of 2028. Moreover, on the basis of test method, the market is segmented into PETIA, ELISA, rapid, and others, out of which, the ELISA segment is expected to garner the highest in-vitro inflammatory bowel disease (IBD) diagnostic market revenue of USD 663.62 Million by the end of 2028, up from a revenue of USD 428.08 Million in 2019.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Disease Type |
|
|
Disease Stage |
|
|
Test Type |
|
|
Patient Demography |
|
|
End-user |
|
Regionally, the in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America industry is estimated to account for largest revenue share of 44% by 2036. backed by the increasing prevalence of IBD amongst the individuals in the region, followed by the presence of a strong healthcare network in countries such as the United States, as well as for the rising healthcare expenditure in the countries in the region. The market in the region garnered a revenue of USD 723.24 Million in the year 2019, and it is further expected to reach USD 1067.01 Million by the end of 2028. The in-vitro inflammatory bowel disease (IBD) diagnostic market in the region is also anticipated to grow with the highest CAGR of 5.7% during the forecast period.
On the other hand, the market in Europe is expected to hold the second-leading market share and attain a revenue of USD 915.66 Million by the end of 2028. Amongst the countries in the region, the in-vitro inflammatory bowel disease (IBD) diagnostic market in Germany is anticipated to garner the second-largest revenue of USD 165.08 Million by the end of 2028, up from a revenue of USD 110.09 Million in 2019.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the in-vitro inflammatory bowel disease (IBD) diagnostic market that are included in our report are
July 12, 2021: Quidel Corporation announced that it has received the CE Mark for two of its products, namely, Savanna multiplex molecular analyzer and Savanna RVP4 Assay (Respiratory Viral Panel-4). The Savanna system, which is an automated in-vitro diagnostic platform, can now be sold in the markets of Europe and other countries where the CE Mark is accepted.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?